We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is inviting web developers to tap into publicly available data on adverse drug events, recalls and labeling and assess their impact for drug research. Read More
A federal judge Friday dismissed Teva, Johnson & Johnson, Endo Health Solutions and Actavis from a lawsuit filed by the city of Chicago alleging use of deceptive marketing to sell opioid-based drugs. Two complaints against a fifth company, Purdue Pharma, will proceed. Read More
Actavis plans to immediately relaunch its generic version of AstraZeneca’s inhaled asthma drug Pulmicort Respules following a federal appeals court decision upholding a lower court ruling that invalidated the brandmaker’s patent on the drug. Read More
The California Supreme Court Thursday held that a pay-to-delay agreement between Bayer and Barr Laboratories over a generic of the brandmaker’s antibiotic Cipro violates the state antitrust law. Read More
Dublin, Ireland-based Amarin Pharmaceuticals is asking a New York federal court to declare its off-label promotion of a cholesterol-lowering drug constitutionally protected free speech, after several FDA rejections of its desire to promote the drug for a wider patient population. Read More
Reckitt Benckiser is voluntarily recalling 1.5 million units of four varieties of its Mucinex liquid cold medicines nationwide because the back labels may not show they contain acetaminophen and other active ingredients. Read More
Gilead Sciences is poised to enter the fledgling field of epigenetics after signing a definitive deal to purchase Denmark-based EpiTherapeutics for $65 million. Read More
Johnson & Johnson’s Janssen subsidiary has enlisted a leading bioethicist to help the company determine who should qualify for compassionate use of its experimental drugs, in what J&J is billing as a first-of-its-kind partnership. Read More